Clinical trial
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease…
NCT00117572 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00117572 |
|---|---|
| Title | Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) |
| Official title | A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer |
| Acronym | DeCIDE |
| Lead sponsor | University of Chicago, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity |
| Intervention type | Drug, Procedure |
| Interventions | docetaxel, cisplatin, hydroxyurea, fluorouracil, chemotherapy, radiotherapy |
| Enrollment | 285 |
| Start date | Nov 1, 2004 |
| Primary completion | Dec 1, 2016 |
| Completion | Dec 1, 2016 |
| First posted | Jul 7, 2005 |
| Last update posted | Apr 9, 2018 |
| Countries | Croatia, France, Russia, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: